Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/28 09:28:33」(JST)
[Wiki en表示]
| Solute carrier organic anion transporter family, member 1B1 |
| Identifiers |
| Symbols |
SLCO1B1 ; HBLRR; LST-1; LST1; OATP-C; OATP1B1; OATP2; OATPC; SLC21A6 |
| External IDs |
OMIM: 604843 HomoloGene: 74575 IUPHAR: 1220 ChEMBL: 1697668 GeneCards: SLCO1B1 Gene |
| Gene ontology |
| Molecular function |
• sodium-independent organic anion transmembrane transporter activity
|
| Cellular component |
• plasma membrane
• integral component of plasma membrane
• membrane
• basolateral plasma membrane
|
| Biological process |
• bile acid metabolic process
• organic anion transport
• bile acid and bile salt transport
• sodium-independent organic anion transport
• small molecule metabolic process
• transmembrane transport
|
| Sources: Amigo / QuickGO |
|
| Orthologs |
| Species |
Human |
Mouse |
|
| Entrez |
10599 |
n/a |
|
| Ensembl |
ENSG00000134538 |
n/a |
|
| UniProt |
Q9Y6L6 |
n/a |
|
| RefSeq (mRNA) |
NM_006446 |
n/a |
|
| RefSeq (protein) |
NP_006437 |
n/a |
|
| Location (UCSC) |
Chr 12:
21.28 – 21.39 Mb |
n/a |
|
| PubMed search |
[1] |
n/a |
|
|
|
Solute carrier organic anion transporter family member 1B1 is a protein that in humans is encoded by the SLCO1B1 gene.[1][2] Pharmacogenomic research indicates that genetic variations in this gene are associated with response to simvastatin.[3] Clinical guidelines exist that can guide dosing of simvastatin based on SLCO1B1 gene variant using genotyping or whole exome sequencing.[4]
See also
References
- ^ Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H (Jul 1999). "Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1". J Biol Chem 274 (24): 17159–63. doi:10.1074/jbc.274.24.17159. PMID 10358072.
- ^ "Entrez Gene: SLCO1B1 solute carrier organic anion transporter family, member 1B1".
- ^ Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M (2013). "SLCO1B1 Genetic Variant Associated with Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink". Clinical Pharmacology & Therapeutics 94 (6): 695–701. doi:10.1038/clpt.2013.161. PMC 3831180. PMID 23942138.
- ^ Huser V, Cimino JJ (2013). "Providing pharmacogenomics clinical decision support using whole genome sequencing data as input". AMIA Summits on Translational Science proceedings AMIA Summit on Translational Science 2013: 81. PMC 3814493. PMID 24303303.
Further reading
- Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG (2000). "A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters". J. Biol. Chem. 274 (52): 37161–8. doi:10.1074/jbc.274.52.37161. PMID 10601278.
- König J, Cui Y, Nies AT, Keppler D (2000). "A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane". Am. J. Physiol. Gastrointest. Liver Physiol. 278 (1): G156–64. PMID 10644574.
- Rollinger-Holzinger I, Eibl B, Pauly M, Griesser U, Hentges F, Auer B, Pall G, Schratzberger P, Niederwieser D, Weiss EH, Zwierzina H (2000). "LST1: a gene with extensive alternative splicing and immunomodulatory function". J. Immunol. 164 (6): 3169–76. doi:10.4049/jimmunol.164.6.3169. PMID 10706707.
- König J, Cui Y, Nies AT, Keppler D (2000). "Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide". J. Biol. Chem. 275 (30): 23161–8. doi:10.1074/jbc.M001448200. PMID 10779507.
- Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A (2000). "Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family". Biochem. Biophys. Res. Commun. 273 (1): 251–60. doi:10.1006/bbrc.2000.2922. PMID 10873595.
- Cui Y, König J, Leier I, Buchholz U, Keppler D (2001). "Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6". J. Biol. Chem. 276 (13): 9626–30. doi:10.1074/jbc.M004968200. PMID 11134001.
- Tirona RG, Leake BF, Merino G, Kim RB (2001). "Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans". J. Biol. Chem. 276 (38): 35669–75. doi:10.1074/jbc.M103792200. PMID 11477075.
- Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA (2001). "Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha". J. Biol. Chem. 276 (40): 37206–14. doi:10.1074/jbc.M103988200. PMID 11483603.
- Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T (2002). "Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis". J. Pharmacol. Exp. Ther. 302 (2): 804–13. doi:10.1124/jpet.302.2.804. PMID 12130747.
- Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J (2003). "A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter". J. Biol. Chem. 277 (45): 43058–63. doi:10.1074/jbc.M207735200. PMID 12196548.
- Tirona RG, Leake BF, Wolkoff AW, Kim RB (2003). "Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation". J. Pharmacol. Exp. Ther. 304 (1): 223–8. doi:10.1124/jpet.102.043026. PMID 12490595.
- Wang P, Kim RB, Chowdhury JR, Wolkoff AW (2003). "The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport". J. Biol. Chem. 278 (23): 20695–9. doi:10.1074/jbc.M301100200. PMID 12670950.
- Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003). "Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics". Clin. Pharmacol. Ther. 73 (6): 554–65. doi:10.1016/S0009-9236(03)00060-2. PMID 12811365.
- Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT (2005). "High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)". Pharmacogenetics 14 (7): 429–40. doi:10.1097/01.fpc.0000114750.08559.32. PMID 15226675.
- Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS (2005). "Risk factors for severe hyperbilirubinemia in neonates". Pediatr. Res. 56 (5): 682–9. doi:10.1203/01.PDR.0000141846.37253.AF. PMID 15319464.
- Campbell SD, de Morais SM, Xu JJ (2005). "Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia". Chem. Biol. Interact. 150 (2): 179–87. doi:10.1016/j.cbi.2004.08.008. PMID 15535988.
- Huang CS, Huang MJ, Lin MS, Yang SS, Teng HC, Tang KS (2005). "Genetic factors related to unconjugated hyperbilirubinemia amongst adults". Pharmacogenet. Genomics 15 (1): 43–50. doi:10.1097/01213011-200501000-00007. PMID 15864125.
- Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB (2006). "Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics". Clin. Pharmacol. Ther. 79 (3): 186–96. doi:10.1016/j.clpt.2005.11.003. PMID 16513443.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
|
Membrane proteins, carrier proteins: membrane transport proteins solute carrier (TC 2A)
|
|
|
|
|
|
Ion pumps
|
|
| Symporter, Cotransporter |
- Na+/K+,l-
- Na/Pi3
- Na+/Cl-
- Na/glucose
- Na+/I-
- Cl-/K+
|
|
| Antiporter (exchanger) |
- Na+/H+
- Na+/Ca2+
- Na+/(Ca2+-K+) - Cl-/HCO3- (Band 3)
- Cl-formate exchanger
- Cl-oxalate exchanger
|
|
|
|
|
see also solute carrier disorders
|
Index of cells
|
|
| Description |
- Structure
- Organelles
- peroxisome
- cytoskeleton
- centrosome
- epithelia
- cilia
- mitochondria
- Membranes
- Membrane transport
- ion channels
- vesicular transport
- solute carrier
- ABC transporters
- ATPase
- oxidoreduction-driven
|
|
| Disease |
- Structural
- peroxisome
- cytoskeleton
- cilia
- mitochondria
- nucleus
- scleroprotein
- Membrane
- channelopathy
- solute carrier
- ATPase
- ABC transporters
- other
- extracellular ligands
- cell surface receptors
- intracellular signalling
- Vesicular transport
- Pore-forming toxins
|
|
|
English Journal
- [[Inflammation and drug metabolism: NF-kappB and the CAR and PXR xeno-receptors].
- Pascussi JM1, Vilarem MJ.
- Médecine sciences : M/S.Med Sci (Paris).2008 Mar;24(3):301-5. doi: 10.1051/medsci/2008243301.
- Decreased drug metabolism, hyperbilirubinemia and intrahepatic cholestasis are frequently observed during inflammation. Additionally, it has long been appreciated that exposure to drug metabolism-inducing xenobiotics can impair immune function. The nuclear receptor CAR (constitutive androstane recep
- PMID 18334180
- Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
- Huang Y.
- Cancer metastasis reviews.Cancer Metastasis Rev.2007 Mar;26(1):183-201.
- Inter-individual variability in drug response and the emergence of adverse drug reactions are main causes of treatment failure in cancer therapy. Recently, membrane transporters have been recognized as an important determinant of drug disposition, thereby affecting chemosensitivity and -resistance.
- PMID 17323126
- Genotype and phenotype relationship in drug metabolism.
- Roots I1, Laschinski G, Arjomand-Nahad F, Kirchheiner J, Schwarz D, Brockmöller J, Cascorbi I, Gerloff T.
- Ernst Schering Research Foundation workshop.Ernst Schering Res Found Workshop.2007;(59):81-100.
- Pharmacogenetics, one of the fields of clinical pharmacology, studies how genetic factors influence drug response. If hereditary traits are taken into account appropriately before starting drug treatment, the type of drug and its dosage can be tailored to the individual patient's needs. Today, the r
- PMID 17117716
Japanese Journal
- P-407 セリバスタチン製剤服用により横紋筋融解症となった患者のOATP-2 (SLC21A6)遺伝子解析(1.薬物療法(基礎と臨床)3,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
- 藤平 文,石川 稚佳子,齋藤 誠麗,大林 雅彦,安生 紗枝子,白井 厚治,井ノ上 逸郎
- 日本医療薬学会年会講演要旨集 15, 330, 2005-09-01
- NAID 110006960646
- Similarity and dissimilarity of LST-1/OATP2/OATP-C (SLC21A6) and OATP8/LST-2 (SLC21A8)
- UNNO Michiaki,ABE Takaaki
- Journal of gastroenterology 38(1), 108-109, 2003-01-01
- NAID 10012736839
- The human organic anion transport protein SLC21A6 (OATP2) is not sufficient for bilirubin transport
Related Links
- SLC21A6 - definition of SLC21A6 by Medical dictionary http://medical-dictionary.thefreedictionary.com/SLC21A6 Printer Friendly Dictionary, Encyclopedia and Thesaurus - The Free Dictionary 7,495,368,414 visitors served Search / Page tools
- Top of page Results The Reactivity of the Monoclonal Antibodies mESL and mMDQ Two epitope-bearing peptides of human SLC21A6 were chosen for the immunization of the mice (Fig. 1): The amino-terminal peptide ...
Related Pictures
